Imricor signed distribution agreement to facilitate sales in Australia and NZ

2021-04-01 02:17:50 (AET) by Ring Zhang   527


Imricor Medical Systems (ASX: IMR) signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.

Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.

Further to that, RHCG will also provide assistance with regulatory approvals in Australia and New Zealand for Imicor's product, with first approvals expected by year-end 2021.

Regional Health Care Group is an Australian-owned business with over 40 years of experience in the medical industry as a provider of medical consumables, contrast media, and capital equipment.

Imricor’s Chair and CEO, Steve Wedan, commented: “We are thrilled to join forces with Regional Healthcare Group to bring Imricor’s products and MRI-guided ablations to Australia and New Zealand. This is an important part of our geographical expansion plans, and we can’t think of a better partner to work with. Together, we look forward to helping improve the care of Australians and New Zealanders struggling with cardiac arrhythmias.”

RHCG General Manager Stephen Doorey added “We are extremely excited to partner with Imricor, their innovative and exciting new solution for Cardiac Ablations is a great addition to our business. RHCG has unrivalled experience in supplying and servicing medical equipment and consumables to the Radiology and Cardiology sector across Australia and New Zealand with over 1,200 devices installed.”

A bit intro about Imricor

Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.

Stock Chart

The share price of IMR moved up by 3.70% to $2.24.

text


Sources: IMR ASX Announcement


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
矿产开发商Dart Mining (DTM) 在维州矿内发现了多种战略性金属,包括锂钽铯锡铌铍等元素

矿产开发商Dart Mining (ASX: DTM) 发出公告宣布,其正在进行的勘探、项目开发和收购突显了澳大利亚维多利亚州东北部包括锂Li、铯Cs、钽Ta和锡Sn在内的关键技术金属的多样化前景和矿化潜力。2016年,Dart Mining的地质学家首次发现了维多利亚东北部Dorchap Range伟晶岩岩脉的锂矿前景,并立即开始在该地区购买和申请勘探租约。这是在澳大利亚东部发现的第一批有记录的锂伟晶岩。

cover
2021有效提高交易能力的机会都在这里

AETOS艾拓思推陈出新,全新打造VIP客户私密培训计划,通过小班授课和定制化教学,与投资人分享机构专业交易团队持续稳定盈利的秘密,让每一位参与者都能实实在在的有效提升交易能力。

相关文章

cover
医疗器械开发商Imricor产品获得澳洲TGA认证

医疗器械开发商Imricor Medical Systems, Inc.(ASX:IMR) 今日发出公告,称拓展取得重要的里程碑——其开发的Advantage-磁共振电生理记录仪/刺激器系统 (记录仪/刺激器) 系统获得了澳大利亚药监局TGA的批准。TGA目前也在对该公司配套的Vision-MR消融导管进行审查。

cover
医疗设备开发商Imricor发出季度报告,三大市场扩展策略全力推进

磁共振引导心脏消融产品的全球领导者Imricor Medical Systems (ASX:IMR) 今日发布其截至2021年6月30日的季度现金流报告并提供财务和运营业绩的季度更新。季度内,该公司新增一个新站点——Helios Hospital Berlin-Buch。公司表示,虽然其分销管道仍然强劲,但由于冠状病毒病 (COVID-19) 带来的长期影响,以及6月和7月的接种率低于预期,新iCMR站点的合同签署进度比预期要慢。

cover
心脏消融设备公司Imricor签署其第十个iCMR实验室站点

可视化心脏消融设备公司Imricor Medical Systems,Inc.( ASX:IMR)宣布,已与德国柏林布赫Helios综合性医院(Helios Hospital Berlin-Buch)签署协议,成为第十个建立iCMR(介入性心脏磁共振成像)实验室的临床站点,将采用Imricor的产品在由MRI引导的环境下进行可视化的心脏消融手术。